Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/57998 |
Resumo: | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
id |
RCAP_a91baff2e458d5e0b328beee2cbbc8f3 |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/57998 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trialTemporomandibular disorderBotulinum toxinIncobotulinumtoxinATemporomandibular joint arthroscopy© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Background: Several studies have considered Botulinum Neurotoxin Type A injections effective in treating temporomandibular joint disorder (TMD) symptoms. A double-blind, randomized, controlled clinical trial investigated the benefit of complementary incobotulinumtoxinA (inco-BoNT/A) injections in the masticatory muscles of patients submitted to bilateral temporomandibular joint (TMJ) arthroscopy. Methods: Fifteen patients with TMD and an indication for bilateral TMJ arthroscopy were randomized into inco-BoNT/A (Xeomin, 100 U) or placebo groups (saline solution). Injections were carried out five days before TMJ arthroscopy. The primary outcome variable was a Visual Analogue Scale for TMJ arthralgia, and secondary outcomes were the myalgia degree, maximum mouth opening, and joint clicks. All outcome variables were assessed preoperatively (T0) and postoperatively (T1—week 5; T2—6-month follow-up). Results: At T1, the outcomes in the inco-BoNT/A group were improved, but not significantly more than in the placebo group. At T2, significant improvements in the TMJ arthralgia and myalgia scores were observed in the inco-BoNT/A group compared to the placebo. A higher number of postoperative reinterventions with further TMJ treatments were observed in the placebo group compared to inco-BoNT/A (63% vs. 14%). Conclusions: In patients submitted to TMJ arthroscopy, statistically significant long-term differences were observed between the placebo and inco-BoNT/A groups.MDPIRepositório da Universidade de LisboaÂngelo, DavidSanz, DavidMaffia, FrancescoCardoso, Henrique José2023-06-06T14:40:46Z20232023-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/57998engToxins 2023, 15(6), 37610.3390/toxins150603762072-6651info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:06:46Zoai:repositorio.ul.pt:10451/57998Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:08:23.725584Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial |
title |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial |
spellingShingle |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial Ângelo, David Temporomandibular disorder Botulinum toxin IncobotulinumtoxinA Temporomandibular joint arthroscopy |
title_short |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial |
title_full |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial |
title_fullStr |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial |
title_full_unstemmed |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial |
title_sort |
Outcomes of IncobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial |
author |
Ângelo, David |
author_facet |
Ângelo, David Sanz, David Maffia, Francesco Cardoso, Henrique José |
author_role |
author |
author2 |
Sanz, David Maffia, Francesco Cardoso, Henrique José |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Ângelo, David Sanz, David Maffia, Francesco Cardoso, Henrique José |
dc.subject.por.fl_str_mv |
Temporomandibular disorder Botulinum toxin IncobotulinumtoxinA Temporomandibular joint arthroscopy |
topic |
Temporomandibular disorder Botulinum toxin IncobotulinumtoxinA Temporomandibular joint arthroscopy |
description |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-06-06T14:40:46Z 2023 2023-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/57998 |
url |
http://hdl.handle.net/10451/57998 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Toxins 2023, 15(6), 376 10.3390/toxins15060376 2072-6651 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134638498643968 |